Meta-analysis of sentinel lymph node positivity in thin melanoma (≥1 mm)

Cancer

Volumn 115, Issue 4, 2009, Pages 869-879

  Warycha, Melanie A ^a   Zakrzewski, Jan ^a   Ni, Quanhong ^b   Shapiro, Richard L ^a   Berman, Russell S ^a   Pavlick, Anna C ^a   Polsky, David ^a   Mazumdar, Madhu ^b   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Lymph node metastases; Sentinel lymph node; Sentinel lymph node biopsy; Thin melanoma

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER RISK; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PATIENT IDENTIFICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MITOSIS; PERIODICALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 60849102449     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24044     Document Type: Article

References (63)

1. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98: 1223-1231.
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
3. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-3676.
4. Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society. J Clin Oncol. 2004;22:3660-3667.
5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
6. Garbe C, Ellwanger U, Tronnier M, Brocker EB, Orfanos CE. The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma Registry. Cancer. 2002;94:2305-2307.
7. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21:1326-1331.
8. Olah J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149:662-663.
9. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247-258.
10. Oliveira Filho RS, Ferreira LM, Biasi LJ, Enokihara MM, Paiva GR, Wagner J. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36:347-350.
11. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449-458.
12. Chakera AH, Drzewiecki KT, Eigtved A, Juhl BR. Sentinel node biopsy for melanoma: a study of 241 patients. Melanoma Res. 2004;14:521-526.
13. Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134:542-547; discussion 547-548.
14. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302-309.
15. Gimotty PA, Botbyl J, Soong SJ, Guerry D. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2005;23: 8065-8075.
16. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumour thickness as a predictor of occult lymph node me- tastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg. 2002;89:1223-1227.
17. Sutton AJ, Jones DR, Abrams KR, Sheldon TA, Song F. Methods for Meta-analysis in Medical Research. Chichester, UK: John Wiley & Sons; 2000.
18. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. Aust N Z J Surg. 2003;73:712-716.
19. Cochran WG, Cox GM. Experimental Designs. 2nd ed. New York, NY: John Wiley & Sons; 1957.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
21. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004;11:900-906.
22. Cecchi R, Buralli L, Innocenti S, De Gaudio C. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34:512-515.
23. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg. 2003;50:601-606.
24. Starz H, Balda BR. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of148 patients. Int J Cancer. 2007;121:689-693.
25. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10:558-561.
26. Lowe JB, Hurst E, Moley JF, Cornelius LA. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617-621.
27. Mazzuca N, Bagnoni G, Solimeo C, et al. Sentinel node biopsy in clinical stage 1 melanoma: rationale for restaging and follow-up. Tumori. 2000;86:351-353.
28. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol. 2006;93:279-285.
29. Vaquerano J, Kraybill WG, Driscoll DL, Cheney R, Kane JM III. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:198-204.
30. MacNeill KN, Ghazarian D, McCready D, Rotstein L. Sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Ann Surg Oncol. 2005;12:726-732.
31. Gipponi M, Di Somma C, Peressini A, et al. Sentinel lymph node biopsy in patients with stage I/II melanoma: clinical experience and literature review. J Surg Oncol. 2004;85:133-140.
32. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13:1655-1663.
33. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569-574.
34. Roka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005;92:662-667.
35. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol. 2005; 141:1016-1022.
36. Kaur C, Thomas R, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61:297-300.
37. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: 2-step prognostic indicators of survival. J Clin Oncol. 2006;24:4464-4471.
38. Statius Muller MG, van Leeuwen PA, van Diest PJ, Vuyl- steke RJ, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res. 2001;11:303-307.
39. Koskivuo I, Suominen E, Niinikoski J, Talve L. Sentinel node metastasectomy in thin < or =1-mm melanoma. Langenbecks Arch Surg. 2005;390:403-407.
40. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Causes Control. 2005;12:230-235.
41. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ III. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:927-932.
42. Carlson GW, Murray DR, Lyles RH, Hestley A, Cohen C. Sentinel lymph node biopsy in the management of cutaneous head and neck melanoma. Plast Reconstr Surg. 2005;115:721-728.
43. Nguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001;181:8-11.
44. Cuellar FA,Vilalta A, Rull R, et al. Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res. 2004;14:277-282.
45. Borgognoni L, Urso C, Vaggelli L, Brandani P, Gerlini G, Reali UM. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. Melanoma Res. 2004;14:311-319.
46. Minutilli E, Giannarelli D, Anza M, et al. Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. J Exp Clin Cancer Res. 2007;26:71-76.
47. Melanoma: Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, v.2. 2007. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/melanoma.pdf.
48. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30- year clinical experience. Ann Surg. 2003;238:528-535; discussion 535-537.
49. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603-608.
50. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology. 1990;17:389-395.
51. Brogelli L, Reali UM, Moretti S, Urso C. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res. 1992;2:87-91.
52. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15:316-322.
53. Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol. 1993;20:126-129.
54. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134.
55. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-273.
56. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
57. Fincher TR, McCarty TM, Fisher TL, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg. 2003;186:675-681.
58. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7:469-474.
59. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.
60. Statius Muller MG, Borgstein PJ, Pijpers R, et al. Reliability of the sentinel node procedure in melanoma patients: analysis of failures after long-term follow-up. Ann Surg Oncol. 2000;7:461-468.
61. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144-150.
62. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J Plast Reconstr Aes- thet Surg. 2008;61:265-271.
63. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. 2003;238:538-549; discussion 549-550.